Search icon

DRINKSAVVY, INC.

Company claim

Is this your business?

Get access!

Company Details

Name: DRINKSAVVY, INC.
Jurisdiction: New York
Legal type: FOREIGN BUSINESS CORPORATION
Status: Active
Date of registration: 18 Oct 2013 (12 years ago)
Entity Number: 4474672
ZIP code: 11226
County: Kings
Place of Formation: Delaware
Address: 760 PARKSIDE AVENUE, BROOKLYN, NY, United States, 11226
Principal Address: 760 PARKSIDE AVE, ROOM 313, BROOKLYN, NY, United States, 11226

DOS Process Agent

Name Role Address
BRENDAN WALKER DOS Process Agent 760 PARKSIDE AVENUE, BROOKLYN, NY, United States, 11226

Chief Executive Officer

Name Role Address
BRENDAN WALKER Chief Executive Officer 760 PARKSIDE AVENUE, ROOM 313, BROOKLYN, NY, United States, 11226

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

E-Commerce Website:
Phone Number:
E-mail Address:
Contact Person:
JACOB TREVINO
User ID:
P2160341
Trade Name:
DRINKSAVVY INC

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
7JZ83
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2024-08-20
CAGE Expiration:
2029-08-20
SAM Expiration:
2025-08-17

Contact Information

POC:
JACOB TREVINO
Phone:
+1 734-787-2171

History

Start date End date Type Value
2017-10-13 2019-10-22 Address 68 3RD STREET, UNIT 243, BROOKLYN, NY, 11231, USA (Type of address: Chief Executive Officer)
2017-10-13 2019-10-22 Address 68 3RD STREET, UNIT 243, BROOKLYN, NY, 11231, USA (Type of address: Principal Executive Office)
2017-10-13 2019-10-22 Address 68 3RD STREET, UNIT 243, BROOKLYN, NY, 11231, USA (Type of address: Service of Process)
2015-11-18 2017-10-13 Address 157 COLUMBUS AVE, NEW YORK, NY, 10023, USA (Type of address: Chief Executive Officer)
2015-11-18 2017-10-13 Address 157 COLUMBUS AVE, NEW YORK, NY, 10023, USA (Type of address: Principal Executive Office)

Filings

Filing Number Date Filed Type Effective Date
191022060282 2019-10-22 BIENNIAL STATEMENT 2019-10-01
171013006222 2017-10-13 BIENNIAL STATEMENT 2017-10-01
151118006134 2015-11-18 BIENNIAL STATEMENT 2015-10-01
131018000320 2013-10-18 APPLICATION OF AUTHORITY 2013-10-18

USAspending Awards / Financial Assistance

Date:
2023-01-02
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
DEVELOPMENT OF A COLORIMETRIC SENSOR FOR DETECTION OF CEREBROSPINAL FLUID LEAKS - PROJECT SUMMARY CHEMELEON, INC. IS A NYC-BASED STARTUP THAT IS DEVELOPING A NOVEL COLORIMETRIC BIOSENSOR THAT RAPIDLY DIAGNOSES CEREBROSPINAL FLUID (CSF) LEAKS AT THE POINT-OF-CARE (POC), SUCH AS BY DOCTORS TO DIAGNOSE TRAUMATIC BRAIN INJURY (TBI) PATIENTS IN THE EMERGENCY DEPARTMENT (ED), OR THE EMERGENCY MEDICAL TECHNICIAN (EMT) IN THE AMBULANCE, OR DURING INTRAOPERATIVE AND POST-OPERATIVE CARE FOR SPINAL AND OTOLARYNGOLOGICAL SURGERIES. CSF LEAKS OCCUR WHEN THE FLUID THAT CUSHIONS THE BRAIN AND SPINE ESCAPES THROUGH RUPTURES IN THE SURROUNDING MEMBRANES. THESE LEAKS ARE LARGELY CAUSED BY TBIS BUT ARE ALSO A RISK DURING SPINAL SURGERIES, OTOLARYNGOLOGICAL SURGERIES, LUMBAR PUNCTURES AND EPIDURALS AND THEY CAN ALSO BE SPONTANEOUS. DISTINGUISHING CSF LEAKS FROM OTHER BODILY FLUIDS IS A WELL-KNOWN PROBLEM FOR ED DOCTORS, EMTS AND SURGEONS AS THE LEAKS OFTEN PRESENT AS UNILATERAL RHINORRHEA OR OTORRHEA, A CLEAR WATERY DISCHARGE FROM THE NOSE OR EAR, OR AS A MIXTURE WITH BLOOD AND OTHER FLUIDS DURING SPINAL SURGERY. CURRENTLY THERE ARE NO POC DIAGNOSTICS FOR CSF LEAKS AND EXISTING METHODS REQUIRE PATIENT SAMPLES TO BE SENT TO THIRD-PARTY LABORATORIES FOR RESULTS THAT CAN TAKE 4-7 DAYS. TREATMENT DELAYS OR MISDIAGNOSES SIGNIFICANTLY INCREASE THE RISK FOR LIFE-THREATENING MENINGITIS, INFECTIONS AND STROKE. PATIENTS WITH CSF RHINORRHEA THAT DEVELOP MENINGITIS HAVE ALSO HAVE MUCH HIGHER MORBIDITY RATES. ADDITIONALLY, THE WEEKLONG STAY NOT ONLY CAUSES SIGNIFICANT DISTRESS AND DISCOMFORT FOR THE PATIENT, BUT ALSO LEADS TO RADICALLY HIGHER HEALTHCARE COSTS. IN THIS DIRECT-TO-PHASE II PROPOSAL, CHEMELEON AIMS TO ADVANCE CSF LEAK DIAGNOSIS BY DEVELOPING A NOVEL, INEXPENSIVE BIOSENSOR THAT REQUIRES NO ADDITIONAL EQUIPMENT OR PERSONNEL TRAINING THAT CAN PROVIDE RESULTS IN MINUTES, ENABLING MEDICAL PROFESSIONALS TO MAKE TIME-SENSITIVE DECISIONS. CHEMELEON HAS ALREADY SUCCESSFULLY DEVELOPED A PROTOTYPE BINDING-INDUCED NANOSTRUCTURED DYNAMIC SURFACE (BINDS) ASSAY THAT BINDS THE CSF PROTEIN BIOMARKER, BETA-2-TRANSFERRIN (B2TR). THIS BINDS PLATFORM TECHNOLOGY INTEGRATES NANOPHOTONIC REPORTER SURFACES WITH B2TR-SPECIFIC APTAMER RECEPTORS, WHERE BINDING OF B2TR TO THE SENSOR SURFACE ALTERS THE SURFACE ENERGY PRODUCING A VIBRANT COLOR CHANGE THAT IS VISIBLE TO THE NAKED EYE. PROOF-OF- CONCEPT EXPERIMENTS REVEALED THAT CHEMELEON’S BINDS CSF ASSAY COULD DETECT 1 ΜG/ML OF B2TR IN 10 MINUTES, WHICH IS HIGHER THAN THE 4-5 ΜG/ML FOUND IN CSF. FOR DIRECT-TO-PHASE II STUDIES, THE CSF SENSOR WILL BE FURTHER DEVELOPED TO ACHIEVE THE HIGH SPECIFICITY, HIGH SENSITIVITY AND LOW READOUT TIME REQUIRED FOR USE IN CLINICAL AND FIELD SETTINGS. CHEMELEON WILL FOCUS ON (1) OPTIMIZING SENSOR PERFORMANCE TO RAPIDLY DISTINGUISH CSF FROM NASAL FLUID AND BLOOD SAMPLES, (2) FINALIZING MANUFACTURING PROCESSES FOR EFFICIENT SCALE-UP, AND (3) DESIGNING AND TESTING A COMMERCIAL IN VITRO DIAGNOSTIC PROTOTYPE. CHEMELEON’S CSF SENSOR WILL PROVIDE ADVANCEMENTS IN DECISION-MAKING FOR HEAD TRAUMA, SPINAL AND OTOLARYNGOLOGICAL SURGICAL CASES AND PRESENT A MODULAR PLATFORM FOR THE DEVELOPMENT OF OTHER HEALTHCARE DIAGNOSTICS.
Obligated Amount:
1680880.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-01-27
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
67310.00
Total Face Value Of Loan:
67310.00
Date:
2020-06-16
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO PROVIDE LOANS TO RESTORE AS NEARLY AS POSSIBLE THE VICTIMS OF ECONOMIC INJURY TYPE DISASTERS TO PRE-DISASTER CONDITIONS
Obligated Amount:
0.00
Face Value Of Loan:
109500.00
Total Face Value Of Loan:
0.00
Date:
2020-05-02
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
67310.00
Total Face Value Of Loan:
67310.00
Date:
2019-05-10
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
DEVELOPMENT OF A COLORIMETRIC SENSOR FOR DETECTION OF CEREBROSPINAL FLUID LEAKS
Obligated Amount:
225000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Paycheck Protection Program

Date Approved:
2021-01-27
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
67310
Current Approval Amount:
67310
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
67732.3
Date Approved:
2020-05-01
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
67310
Current Approval Amount:
67310
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Male Owned
Veteran:
Non-Veteran
Forgiveness Amount:
67767.34

Reviews Leave a review

This company hasn't received any reviews.

Date of last update: 26 Mar 2025

Sources: New York Secretary of State